Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases

Clinical trial NCT05909618 · RECRUITING

Trial details

NCT number: NCT05909618
Sponsor: Sheba Medical Center
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Glioblastoma Metastatic Melanoma in the Central Nervous System MGMT-Unmethylated Glioblastoma

Start date: 2023-07-11
Primary completion: 2028-07-30
Enrollment: 33

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.